PROCEPT BioRobotics
PRCT
17.91
+0.40
+2.28%
PROCEPT BioRobotics
US · PRCT
#3234 by market cap
Listed 2021
17.91
+0.40
+2.28%
Live - 5344 symbols - heartbeat 229s ago
· 2026-10-08 09:00
Pre-market
18.02
+0.61%
After-hours
17.91
0.00%
- Market cap
- 1.03B
- P/E (TTM)i
- -9.18
- P/Bi
- 3.02
- EPSi
- -1.72
- Div yieldi
- 0.00%
- 52W posi
- 6%
Reader sentiment
Are you bullish or bearish on PRCT?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 3.40, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 7 years
Latest year +37.22% YoY
Margins
- Gross margin
- 63.70%
- Operating margin
- -33.71%
- Net margin
- -31.02%
Key ratios & quality
- Enterprise valuei
- 793.10M
- Altman Z-Scorei
- 3.40
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 6.17M | 7.72M | 34.47M | 75.01M | 136.19M | 224.50M | 308.05M |
| Gross profit | -1.89M | -1.26M | 15.87M | 37.09M | 71.05M | 137.10M | 196.23M |
| Selling & admin expenses | 28.52M | 30.27M | 51.04M | 88.83M | 131.77M | 171.42M | 228.81M |
| Research & development | 13.15M | 16.28M | 18.99M | 28.98M | 48.45M | 62.30M | 71.28M |
| Operating profit | -43.55M | -47.80M | -54.16M | -80.72M | -109.17M | -96.61M | -103.86M |
| Pretax profit | -41.98M | -53.02M | -59.85M | -87.15M | -105.82M | -91.05M | -95.38M |
| Tax | -- | -- | -- | -- | 80.00K | 368.00K | 190.00K |
| Net profit | -41.98M | -53.02M | -59.85M | -87.15M | -105.90M | -91.41M | -95.57M |
| Basic EPS | -1 | -2 | -4 | -2 | -2 | -2 | -2 |
| Diluted EPS | -1.25 | -1.51 | -3.63 | -1.96 | -2.24 | -1.75 | -1.72 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 69.16M | 79.18M | 83.33M | 76.38M | 83.13M | 94.50M |
| Gross profit | 44.16M | 51.75M | 54.01M | 46.31M | 53.95M | 62.38M |
| Selling & admin expenses | 55.20M | 56.30M | 59.01M | 58.30M | 65.09M | 69.67M |
| Research & development | 16.40M | 17.63M | 18.19M | 19.06M | 21.47M | 20.10M |
| Operating profit | -27.44M | -22.19M | -23.19M | -31.04M | -32.61M | -27.39M |
| Pretax profit | -24.78M | -19.44M | -21.41M | -29.66M | -31.68M | -26.77M |
| Tax | -47.00K | 136.00K | -- | -- | -43.00K | 94.00K |
| Net profit | -24.74M | -19.58M | -21.41M | -29.85M | -31.64M | -26.86M |
| Basic EPS | 0 | 0 | 0 | -1 | -1 | 0 |
| Diluted EPS | -0.45 | -0.35 | -0.38 | -0.53 | -0.56 | -0.47 |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Total current assets | 50.74M | 110.26M | 326.17M | 272.63M | 350.57M | 481.84M | 450.38M |
| Cash & ST investments | 42.02M | 100.13M | 304.32M | 221.86M | 257.22M | 333.73M | 286.50M |
| Inventory | 6.69M | 7.48M | 13.15M | 28.54M | 39.76M | 56.17M | 70.69M |
| Total assets | 62.00M | 125.97M | 337.02M | 309.33M | 404.72M | 534.02M | 508.08M |
| Total current liabilities | 6.79M | 14.53M | 16.24M | 35.29M | 45.93M | 53.13M | 65.80M |
| Short-term debt | -- | 6.26M | 2.11M | 2.13M | 1.68M | 1.91M | 2.21M |
| Long-term debt | 23.22M | 44.41M | 50.00M | 51.21M | 51.34M | 51.47M | 51.62M |
| Total liabilities | 205,832,000.00 | 308,865,000.00 | 69,933,000.00 | 112,257,000.00 | 123,965,000.00 | 131,797,000.00 | 142,211,000.00 |
| Total equity | -143.84M | -182.89M | 267.09M | 197.07M | 280.75M | 402.22M | 365.87M |
| Retained earnings | -148.65M | -201.67M | -261.52M | -348.68M | -454.57M | -545.99M | -641.56M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 465.79M | 458.07M | 454.75M | 450.38M | 428.03M | 420.29M |
| Cash & ST investments | 316.21M | 302.72M | 294.28M | 286.50M | 245.64M | 227.91M |
| Inventory | 62.33M | 67.03M | 66.72M | 70.69M | 77.54M | 77.06M |
| Total assets | 519.38M | 513.05M | 511.54M | 508.08M | 487.06M | 479.35M |
| Total current liabilities | 52.06M | 49.73M | 53.90M | 65.80M | 63.64M | 64.20M |
| Short-term debt | 3.98M | 2.06M | 2.14M | 2.21M | 2.36M | 2.51M |
| Long-term debt | 51.50M | 51.52M | 51.57M | 51.62M | 51.66M | 51.72M |
| Total liabilities | 130,218,000.00 | 127,258,000.00 | 131,265,000.00 | 142,211,000.00 | 139,395,000.00 | 139,282,000.00 |
| Total equity | 389.16M | 385.80M | 380.28M | 365.87M | 347.67M | 340.07M |
| Retained earnings | -570.72M | -590.30M | -611.71M | -641.56M | -673.20M | -700.06M |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -43.82M | -48.34M | -57.33M | -80.38M | -108.00M | -99.21M | -48.99M |
| Depreciation & amortization | 1.49M | 2.86M | 3.32M | 2.84M | 3.81M | 5.23M | 6.39M |
| Free cash flow | -51.43M | -48.58M | -57.93M | -83.04M | -133.21M | -103.62M | -58.34M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 0 | 172.36M | 0 | 161.71M | 164.52M | 0 |
| Ending cash balance | 42.71M | 100.91M | 305.10M | 225.67M | 260.26M | 336.76M | 289.54M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -16.98M | -15.04M | -6.64M | -10.33M | -38.13M | -19.25M |
| Depreciation & amortization | 1.48M | 1.59M | 1.62M | 1.71M | 1.74M | 1.99M |
| Free cash flow | -18.82M | -17.85M | -9.50M | -12.18M | -41.04M | -22.20M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 319.25M | 305.76M | 297.32M | 289.54M | 248.68M | 230.95M |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -142.17 | -37.55 | -44.32 | -26.77 | -24.89 |
| ROA %i | -67.71 | -56.41 | -25.85 | -26.97 | -29.66 | -19.48 | -18.34 |
| ROIC %i | -- | -- | -56.06 | -28.37 | -34.51 | -23.30 | -22.49 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -55.14 |
| EBIT margin %i | -668.68 | -618.87 | -156.77 | -109.27 | -74.82 | -38.86 | -29.80 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 7.47 | 7.59 | 20.08 | 7.73 | 7.63 | 9.07 | 6.85 |
| Quick ratioi | 6.35 | 7.00 | 19.01 | 6.72 | 6.65 | 7.85 | 5.62 |
| Debt / assetsi | 37.46 | 43.47 | 16.05 | 25.00 | 19.57 | 15.03 | 15.45 |
| LT debt / equityi | -- | -- | 19.47 | 38.15 | 27.61 | 19.48 | 20.85 |
| Interest coveragei | -56.98 | -9.08 | -9.30 | -15.82 | -25.51 | -20.85 | -25.60 |
| Revenue CAGR (3Y) %i | -- | -- | -- | 129.95 | 160.36 | 86.74 | 60.14 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -27.62 | -26.40 | -27.22 | -24.89 | -27.81 | -30.24 |
| ROA %i | -19.99 | -18.96 | -19.10 | -18.34 | -20.36 | -22.12 |
| ROIC %i | -23.99 | -23.38 | -24.08 | -22.49 | -23.78 | -25.52 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -34.59 | -29.19 | -26.98 | -29.80 | -30.67 | -31.46 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 8.95 | 9.21 | 8.44 | 6.85 | 6.73 | 6.55 |
| Quick ratioi | 7.60 | 7.71 | 7.03 | 5.62 | 5.37 | 5.23 |
| Debt / assetsi | 15.75 | 15.47 | 15.43 | 15.45 | 16.01 | 16.17 |
| LT debt / equityi | 20.00 | 20.04 | 20.19 | 20.85 | 21.76 | 22.05 |
| Interest coveragei | -21.46 | -20.68 | -22.10 | -25.60 | -28.00 | -30.56 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Single segment100.00%
Quote time 2026-10-08 09:00:45 · For reference only, not investment advice and not tailored to your situation.